Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
Open access

Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis

S. Gupta M. Seshadri R. Dandekar L. Mueller-Jensen K. McCutcheon L. A. Scarffe S. Vanasupa M. Sunahara F. Hayashi C. Caspar R. Lincoln N. Okinishi N. Thomas S. Shenoy S. Zylberman C. Fouassier E. Hassan S. Klauer J. Wilmoth J. Sabatino A. Bodansky A. Abdelhak S. Hauser M. Wilson B. Cree
Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

Low dose anti CD19 CAR T cell therapy was safe, penetrated the CSF effectively, reduced intrathecal humoral activity, modulated peripheral immune tone, and appeared to stabilize EDSS scores, which support the continued investigation of CAR T cell therapy in MS.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Sep 2026

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy.

Repeat infusion of chimeric antigen receptor (CAR) T-cell is effective for patients with refractory or relapsed multiple myeloma (RRMM) after failing a prior CAR Tcell therapy. It is unknown whether B-cell maturation antigen (BCMA) CAR T-cell is effective for patients with RRMM after anti-G protein-coupled receptor, cl...

Xiao-Tian Zhang, Fan Xia, Kun-Ming Qi et al. · 0 citations
Open access Sep 2026

Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients

Donor-derived anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has emerged as one of the most promising treatments for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this retrospective study, we evaluated the safety and efficacy of donor-derived anti-CD19 CAR T cells manufactur...

Supavich Tannumsaeng, U. Anurathapan, Arpatsorn Sermcheep et al. · 0 citations
Review Open access Aug 2026

Recognition and management of early complications in CAR-T cell therapy and virus-specific T-lymphocyte therapy: a practical clinical reference

This review summarizes current recommendations for identifying, assessing, and treating early problems that can occur after CAR-T cell therapy and VST administration, and summarizes a differential diagnosis of overlapping syndromes, pediatric-specific adaptations, ICU escalation criteria, and a clinical monitoring sche...

M. Ussowicz, E. Jakubczyk, Tomasz Wróbel et al. · 0 citations
Review Open access Sep 2026

Sequencing CD19-targeted therapies in patients with relapsed/refractory large B-cell lymphoma: A narrative review.

The unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies are discussed, while providing expert clinical practice recommendations to optimize patient outcomes are provided.

P. Caimi, Romano Danesi, G. Iacoboni et al. · 0 citations
Open access Sep 2026

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Exploratory multi-omic profiling linked durable response to higher CD22 antigen density on blasts; pre-infusion CD4 CAR-T cells expressing IL7Rα, LEF1, BACH2, and TCF7 but lower FOXP3; post-infusion NK-like effector CAR-T expansion; and central-memory CAR-T pool maintenance.

M. Seng, Ze-Xi Guo, Kai Soon Ng et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.